Federal Register / Vol. 63, No. 131 /Thursday, July 9, 1998 / Notices 37137

proposed Consent Decree may be

obtained in person or by mail from the

Consent Decree Library, 1120 G Street,

NW., 4th Floor, Washington, DC 20005.

In requesting a copy please refer to the

referenced case and enclose a check in

the amount of $4.25 (25 cents per page

reproduction costs), payable to the

Consent Decree Library.

Joel M. Gross,

Chief, Environmental Enforcement Section,

Environment and Natural Resources Division.

[FR Doc. 98–18253 Filed 7–8–98; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on April 1,

1998, Aernol Pharmaceutical, Inc., 189

Meister Avenue, Somerville, New Jersey

08876, made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the basic classes of controlled

substances listed below.

Drug Schedule

N-Ethylamphetamine (1475) ......... I

Difenoxin (9168) ........................... I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

The firm plans to manufacture the

listed controlled substances to produce

pharmaceutical products for its

customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

September 8, 1998.

Dated: June 10, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–18217 Filed 7–8–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on January 28,

1998, Chiragene, Inc., 7 Powder Horn

Drive, Warren, New Jersey 07059, made

application to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below.

Drug Schedule

N-Ethylamphetamine (1475) ......... I

2,5-Dimethoxyamphetamine

(7396).

I

3,4-Methylenedioxyamphetamine

(7400).

I

4-Methoxyamphetamine (7411) .... I

Amphetamine (1100) .................... II

Methylphenidate (1724) ................ II

The firm plans to manufacture the

listed controlled substances to supply

their customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

September 8, 1998.

Dated: June 10, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–18216 Filed 7–8–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on April 19,

1998, Damocles 10, 3529 Lincoln

Highway, Thorndale, Pennsylvania

19372, made application by renewal to

the Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the basic classes of

controlled substances listed below.

Drug Schedule

Heroin (9200) ................................ I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Phenmetrazine (1631) .................. II

Hydromorphone (9150) ................ II

Morphine (9300) ........................... II

The firm plans to manufacture the

listed controlled substances for the

purpose of deuterium labeled internal

standards for distribution to analytical

laboratories.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

September 8, 1998.

Dated: June 30, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–18219 Filed 7–8–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By notice dated January 21, 1998, and

published in the Federal Register on

February 12, 1998 (63 FR 7181), Johnson

& Johnson Pharmaceutical Partners, HC–

02 Box 19250, KMO.1 Mamey Ward

(HC–02 Box 19250), Gurabo, Puerto Rico

00778–9629, made application by

renewal to the Drug Enforcement

Administration (DEA) to be registered as

a bulk manufacturer of sufentanil

(9740), a basic class of controlled

substance listed in schedule II.

The firm plans to manufacture

sufentanil for bulk distribution to its

customers.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Johnson & Johnson

Pharmaceutical Partners to manufacture

sufentanil is consistent with the public

interest at this time. Therefore, pursuant